Doubts Raised Over Regeneron’s Anti-IL 33 REGN3500 At Phase II In Asthma
Executive Summary
Topline data from a Phase II proof-of-concept study evaluating anti-IL-33 monotherapy REGN3500 (SAR440340) in asthma suggest it is not as effective as Dupixent and that there is no incremental benefit from adding it to Dupixent.